Examining how assisted reproductive technologies affect pregnancy outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort study aims to investigate the relationship between various parameters of assisted reproductive technologies (ART) and perinatal outcomes in both singleton and multiple pregnancies. Researchers will assess whether ART pregnancies are linked to higher risks of conditions such as fetal growth restriction, preeclampsia, and stillbirth, while also examining potential placental and umbilical cord abnormalities. The study will adjust for confounding factors like maternal age and BMI, and will analyze outcomes based on specific ART techniques and protocols. By clarifying these associations, the study seeks to enhance clinical care and counseling for couples considering ART.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Singleton or multiple pregnancies
* Live fetus between 11 weeks plus 0 days and 13 weeks plus 6 days of gestation

Exclusion Criteria

* Known genetic anomalies diagnosed before or after birth
* Major fetal defects diagnosed before or after birth, such as acrania, holoprosencephaly, megacystis, exomphalos, congenital heart defects

Where it's running

• Aristotle University of Thessaloniki
  Thessaloniki, Central Macedonia, Greece Recruiting
• University Hospital of Pleven
  Pleven, Bulgaria Not yet recruiting
• Complejo Hospitalario Universitario de Canarias
  Santa Cruz de Tenerife, Canary Islands, Spain Not yet recruiting
• Universidad Francisco de Vitoria
  Madrid, Spain Not yet recruiting
• Hospital Universitario de Torrejón
  Madrid, Spain Not yet recruiting
• Hospital Clínico Universitario "virgen de la Arrixaca"
  Murcia, Spain Not yet recruiting

Study contacts

• Study coordinator: Themistoklis Dagklis
• Email: dagklis@auth.gr
• Phone: +302313312120

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation

  This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.

  Recruiting at 2 sites Makerere University · Kampala and 1 other locations · NCT07844876

• ASPIRE: Predicting Pregnancy Complications Using Blood and Eye Imaging

  This study tests whether blood and eye imaging biomarkers can predict conditions like preeclampsia, fetal growth restriction, and gestational diabetes in first-time pregnant people carrying one baby.

  Recruiting at 4 sites Medicines360 · Bridgeport, Connecticut and 4 other locations · NCT07669935

• Evaluating new ultrasound techniques for assessing placental health

  This study is testing new ultrasound techniques to see if they can help tell the difference between healthy pregnancies and those with fetal growth issues.

  Recruiting Carilion Clinic · Roanoke, Virginia · NCT06861309

• Treating asymptomatic urinary infection during pregnancy in low- and middle-income countries

  This trial will test whether giving pregnant people with asymptomatic bacteriuria nitrofurantoin (versus placebo) can reduce preterm birth, small-for-gestational-age babies, or stillbirth.

  Recruiting at 2 sites Phase 3 NICHD Global Network for Women's and Children's Health · Dhaka, Bangladesh and 6 other locations · NCT06723392

• Internal jugular vein collapsibility to gauge volume status in preeclampsia vs. normal pregnancy

  This study tests whether ultrasound of the internal jugular vein can show differences in fluid status between preeclamptic pregnant people and those with normal blood pressure during planned cesarean delivery.

  Recruiting Tanta University · Tanta, El-Gharbia Govenorate · NCT07786246

• Higher vs lower daily aspirin in high-risk pregnant people

  This study tests whether taking 150 mg of aspirin daily is more effective than 75 mg daily in preventing preeclampsia among pregnant people at high risk.

  Recruiting Phase 4 Medicare Hospital (Pvt) Limited · Multan, Punjab Province · NCT07779057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.